About this trial
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.
Eligibility criteria
Qualifiers
Multiple Myeloma diagnosis
Scheduled to undergo their first Autologous Stem Cell Transplant procedure.
21years or older
Able to provide informed consent.
Disqualifiers
Previous Autologous Stem Cell Transplant procedure
Pregnancy
Eye diseases which limit the ability of light to be processed
Secondary cancer diagnosis within the last 5 years
Trial design
Treatments tested in this trial
- Circadian Effective Lighting
- Circadian Ineffective Lightning (CIL)